Peptidomimetics for Pancreatic, Colorectal Cancer Diagnostics, Therapeutics
Summary
USPTO published application US20260109745A1 on April 23, 2026, covering peptidomimetics targeting the NPC-1 epitope on the MUC5AC protein, which shows differential expression in pancreatic and colorectal cancer. The application, filed October 24, 2025 under Application No. 19367897 with inventor Xue-Ping Wang, also discloses antibodies that selectively bind the NPC-1 epitope for use in diagnostic and therapeutic methods.
“The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
USPTO published patent application US20260109745A1 covering peptidomimetics of the NPC-1 epitope on MUC5AC protein, which is differentially expressed in pancreatic and colorectal cancer tissues. The application also discloses antibodies that selectively bind these peptidomimetics and their use in diagnostic and therapeutic methods.
Pharmaceutical and biotechnology companies developing cancer diagnostics or targeted therapeutics should review the application to assess potential overlap with their own IP portfolios or licensing opportunities related to MUC5AC-targeted peptidomimetics.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Colon and Pancreas Cancer Peptidomimetics
Application US20260109745A1 Kind: A1 Apr 23, 2026
Inventors
Xue-Ping WANG
Abstract
The invention relates to a peptidomimetic of an NPC-1 epitope on the MUC5AC protein which is differentially expressed in pancreatic and colorectal cancer, and diagnostic and therapeutic usages. Further, antibodies that selectively bind the NPC-1 epitope peptidomimetics and may be used in diagnostic and therapeutic methods.
CPC Classifications
C07K 14/4727 A61K 39/0011 A61K 45/06 A61K 47/64 A61K 47/643 A61K 47/645 A61K 47/646 C07K 14/4748 C07K 16/3092 G01N 33/57525 G01N 33/57535 A61K 38/00 A61K 2039/505 C07K 2317/34 C07K 2317/732 C07K 2319/00 G01N 2333/4725
Filing Date
2025-10-24
Application No.
19367897
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.